Effects of a High‐Fat Meal on the Pharmacokinetics of Olverembatinib in Patients With Chronic Myeloid Leukemia
ABSTRACT Olverembatinib is approved in China to treat patients with chronic‐ or accelerated‐phase chronic myeloid leukemia (CML‐CP or CML‐AP) with T315I mutations and CML‐CP that is resistant and/or intolerant to first‐ and second‐generation tyrosine kinase inhibitors. The objective of this study wa...
Guardat en:
| Autors principals: | , , , , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Wiley
2026-05-01
|
| Col·lecció: | Clinical and Translational Science |
| Matèries: | |
| Accés en línia: | https://doi.org/10.1111/cts.70545 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|